Wumei Pill ameliorates cognitive dysfunction in diabetic encephalopathy via inhibiting astrocyte-derived chemokine-receptor mediated neuroinflammation.
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Wumei Pill (WMP) is a classic traditional Chinese medicine formula recorded in Zhang Zhongjing's Treatise on Febrile Diseases for the treatment of "Xiao Ke" (consumptive thirst, analogous to diabetes mellitus). Historically, it has been used to treat diabetes mellitus and neurological dysfunction. However, its therapeutic effect on diabetic encephalopathy (DE) and the underlying mechanisms remain unclear.
AIM OF THE STUDY: To explore the therapeutic effect of WMP on diabetic encephalopathy and elucidate whether it exerts neuroprotective effects via CXCL1/CXCR2 signaling-mediated neuroinflammation, particularly given the lack of effective treatments for DE and the unclear neuroprotective mechanism of WMP.
MATERIALS AND
METHODS
Leptin receptor-deficient (db/db) mice and high-fat diet/streptozotocin (HFD/STZ)-induced type 2 diabetes mellitus (T2DM) mice were administered WMP intragastrically for 8 weeks. A validated HPLC method was applied to ensure consistent and stable contents of representative bioactive components in all WMP preparations used throughout the study. Cognitive function was evaluated using Morris water maze and novel object recognition tests, while metabolic parameters including body weight (BW) and fasting blood glucose (FBG) were assessed. Hippocampal pathological changes were observed via HE and Nissl staining. Network pharmacology and transcriptomics were performed to screen active components, potential targets, and key differentially expressed genes (DEGs) of WMP against DE. Western blot, ELISA, and immunological assays were used to quantify key protein and cytokine levels. In vitro assays were further conducted to verify the dependence on the target signaling pathway.
RESULTS
WMP reduced BW and FBG, ameliorated cognitive impairments as shown by shortened escape latency, increased platform crossings, and an improved novel object recognition index. It also increased the number of neurons in the hippocampal CA1 and CA3 regions and upregulated the expression of synaptic proteins. Network pharmacology and transcriptomics analysis revealed that the C-X-C motif chemokine ligand 1 (CXCL1)/C-X-C motif chemokine receptor 2 (CXCR2) axis played a key role in WMP-mediated protection against DE. In vivo, WMP significantly inhibited the hippocampal CXCL1/CXCR2 axis and reduced the release of pro-inflammatory cytokines (TNF-α/IL-1β) in diabetic mice. In vitro experiments further demonstrated that WMP exerted neuroprotective effects indirectly rather than directly acting on hippocampal neurons: it notably suppressed high glucose-induced CXCL1 upregulation and protein secretion in astrocytes. Notably, the neuroprotective effect of WMP was abolished by exogenous recombinant CXCL1, confirming the essential role of astrocyte-derived CXCL1.
CONCLUSIONS
WMP ameliorates metabolic disorders and cognitive dysfunction in DE by targeting the astrocyte-neuron CXCL1/CXCR2 axis. This action is mediated by inhibiting astrocytic CXCL1 secretion and subsequent CXCL1/CXCR2-driven neuroinflammation, thus preserving hippocampal neuronal integrity. Our findings reveal a novel mechanism for WMP and provide a promising therapeutic strategy for DE.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.